Viridian Therapeutics Management
Management criteria checks 1/4
Viridian Therapeutics' CEO is Steve Mahoney, appointed in Oct 2023, has a tenure of 1.25 years. total yearly compensation is $13.02M, comprised of 0.9% salary and 99.1% bonuses, including company stock and options. directly owns 0.027% of the company’s shares, worth $410.30K. The average tenure of the management team and the board of directors is 1.3 years and 4.3 years respectively.
Key information
Steve Mahoney
Chief executive officer
US$13.0m
Total compensation
| CEO salary percentage | 0.9% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.03% |
| Management average tenure | 1.3yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$18.7 Based On Its Intrinsic Value?
Dec 20
We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate
Nov 14Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?
Sep 11Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way
Sep 10Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year
Jun 12Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?
May 28Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt
Sep 12Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?
May 15Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?
Apr 18Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?
Jan 08Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market
Sep 09Viridian Therapeutics board compensation committee approves inducement grants
Sep 02An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued
Aug 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$257m |
| Jun 30 2024 | n/a | n/a | -US$228m |
| Mar 31 2024 | n/a | n/a | -US$218m |
| Dec 31 2023 | US$13m | US$113k | -US$238m |
Compensation vs Market: Steve's total compensation ($USD13.02M) is above average for companies of similar size in the US market ($USD5.43M).
Compensation vs Earnings: Insufficient data to compare Steve's compensation with company performance.
CEO
Steve Mahoney (53 yo)
1.3yrs
Tenure
US$13,022,654
Compensation
Mr. Stephen F. Mahoney, also known as Steve, J. D. serves as President, CEO & Director at Viridian Therapeutics, Inc. since October 30, 2023. He served as President, Chief Financial and Operating Officer a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.3yrs | US$13.02m | 0.027% $ 410.3k | |
| Senior VP of Finance and Accounting | 1.3yrs | US$6.67m | 0.0013% $ 19.1k | |
| Chief Operating Officer | 1.3yrs | US$5.17m | 0.0076% $ 115.0k | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of the Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Co-Founder & Scientific Advisor | no data | no data | no data | |
| Chief Legal Officer | less than a year | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Chief Human Resources Officer | less than a year | no data | no data | |
| Chief Commercial Officer | 1.8yrs | no data | no data | |
| Chief Medical Officer | 2yrs | no data | 0.00096% $ 14.6k |
1.3yrs
Average Tenure
53.5yo
Average Age
Experienced Management: VRDN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.3yrs | US$13.02m | 0.027% $ 410.3k | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of the Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Independent Director | 7yrs | US$477.83k | 0% $ 0 | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Independent Chairperson of Board | 4.3yrs | US$503.83k | 0% $ 0 | |
| Independent Director | 3.5yrs | US$467.83k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$471.83k | 0% $ 0 |
4.3yrs
Average Tenure
53yo
Average Age
Experienced Board: VRDN's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 00:35 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Viridian Therapeutics, Inc. is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Madhu Kumar | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |